FDA creates faster way to access over-the-counter naloxone products to treat opioid overdoses

The following is cross-posted from our Optum Insights—Government Affairs blog The U.S. Food and Drug Administration (FDA) recently established a more rapid path for pharmaceutical companies to add over-the-counter (OTC) naloxone products to the market to increase access to naloxone – a life-saving medication used for the emergency treatment of opioid-related overdose – and help … Read moreFDA creates faster way to access over-the-counter naloxone products to treat opioid overdoses

Lyrica® generic delayed until summer 2019 and Pfizer to increase drug prices

This is a cross-post from our Optum Insights blog. The U.S. Food and Drug Administration’s (FDA) recent decision to grant pediatric exclusivity for Lyrica® ― as it may be used as an adjunctive therapy for partial onset seizures in pediatric epilepsy patients ― extends the period of market exclusivity in the U.S. by an additional … Read moreLyrica® generic delayed until summer 2019 and Pfizer to increase drug prices

Updated Medicare Secondary Payer Recovery Portal User Guide Released

This post is written by James Martinez of Optum Settlement Solutions. On July 2, 2018, the Centers for Medicare and Medicaid Services (CMS) released limited changes in version 4.2 of its Medicare Secondary Payer Recovery Portal (MSPRP) User Guide. This new information aims to provide electronically current and consistent conditional payment information.  In addition, the … Read moreUpdated Medicare Secondary Payer Recovery Portal User Guide Released